30 closest matches · ranked by relevance
Complicated Intra-abdominal Infection
Primary: The Percentage of Subjects With Clinical Outcome of Cure at the Test of Cure (TOC) Visit in the Microbiological Intent to Treat (MITT) Population — 83.0; 87.3 percentage…
Intra Abdominal Infections
Primary: Percentage of Participants With Clinical Success — 85.5; 90.2 percentage of participants
Appendicitis · Cholecystitis · Cross Infection
Primary: Number of Clinically Evaluable Patients With Clinical Response of Cure at Test-of-Cure (TOC) Visit. — 133; 139 participants — p=0.009
Complicated Intra-abdominal Infection
Primary: Clinical Response of CXA 101/Tazobactam and Metronidazole at Test of Cure (TOC) Visit in the Microbiological Modified Intent to Treat (mMITT) Analysis Population — 83.6…
Complicated Intra-abdominal Infections
Primary: Percentage of Participants With Clinical Response (Clinical Cure or Clinical Failure) at Test of Cure (TOC) Visit: Clinically Evaluable (CE) Population — 95.2; 93.1…
Complicated Intra-abdominal Infections
Primary: Clinical Response of Eravacycline and Ertapenem Treatment Arms at the Test-of-cure (TOC) Visit in the Microbiological Intent-to-treat (Micro-ITT) Population — 191; 198…
Complicated Intra-abdominal Infection
Primary: Clinical Response to TP-434 and Ertapenem in the Microbiologically Evaluable (ME) Population at the Test-of-Cure Visit — 39; 41; 24; 3 participants
Complicated Intra-abdominal Infections · Complicated Appendicitis
Primary: Number of Participants With a Favorable Clinical Response at the Test-of-Cure (TOC) Visit in the Microbiological Intent-to-treat (Micro-ITT) Population — 177; 187; 7; 7…
Appendicitis · Cholecystitis · Diverticulitis
Primary: Number of Clinically Evaluable (CE) Patients With Clinical Response of Cure at the Test-of-Cure (TOC) Visit — 162; 150 participants
Complicated Intra-abdominal Infections
Primary: Percentage of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) — 52.5; 59.1; 8.2; 4.5 percentage of participants
Infection
Primary: Number of Subjects Achieving Clinical Cure at Test of Cure (TOC) Visit in the Per Protocol Population — 315; 324; 37; 23 participants
Complicated Intra-Abdominal Infection
Primary: Clinical Response at the Test of Cure (TOC) Visit in the Microbiologically Modified Intent-To-Treat (mMITT) Analysis Set (Primary Outcome for FDA). — 337; 349; 37; 30…
Intra-abdominal Infection · Complicated Intra-abdominal Infection
Primary: Percentage of Participants With Clinical Response (Clinical Cure, Clinical Failure, or Indeterminate) at Test of Cure (TOC) — 92.0; 8.0; 0.0 Percentage of Participants
Intra-abdominal Infection
Primary: Clinical Response at the Test-of-Cure (TOC) Assessment Within the Clinically Evaluable (CE) Population — 89.9; 96.6; 10.1; 3.4 percentage of participants — p=0.0008
Complicated Intra-abdominal Infections
Primary: Number of Participants With Clinical Response at the Test of Cure (TOC) Visit — 62; 71 participants
Intra-abdominal Infections
Primary: Percentage of Participants With a Favorable Clinical Response at Completion of IV Study Therapy — 96.3; 98.8; 95.2 Percentage of participants — p=< 0.001
Intra-Abdominal Infections · Skin Disease, Infectious · Soft Tissues Infections
Primary: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) — 11; 45; 4; 28 participants
Complicated Urinary Tract Infection · Complicated Intra-abdominal Infection
Primary: Clinical Response at Test of Cure (TOC) in Microbiological Modified Intent-to-treat (mMITT) Analysis Set — 6; 8; 129; 132 Participant
Complicated Intra-abdominal Infection
Primary: The Proportion of Patients With Clinical Cure at the Test of Cure (TOC) Visit in the Clinically Evaluable (CE) Analysis Set. — 166; 173; 11; 11 Number of patients…
Complicated Intra-Abdominal Infection
Primary: Number of Participants Experiencing ≥1 Adverse Events (AEs) — 56; 13 Participants
Complicated Intra-Abdominal Infection
Primary: Duration of Hospitalization — 14.1 Days
Complicated Intra-abdominal Infection
Primary: Number of Participants With Clinical Response at Test of Cure (TOC) Visit: Clinically Evaluable (CE) Analysis Set — 36; 4; 0 Participants
Intra-Abdominal Infections · Intestinal Obstruction · Appendicitis Acute
Primary: Number of Participants Who Died by Day 28 — 8; 23 Participants — p=0.001
Intraabdominal Infections
Primary: Number of Subjects With Adverse Events — 175; 82; 20; 6 Subjects
Abdominal (ABD) Infection
Primary: Extended-Spectrum Days of Antibacterial Therapy (ES-DOT) Per Empiric Day — 68616; 68679; 76605; 50001 Extended-Spectrum Days-of-Therapy
Complicated Intra Abdominal Infections
Primary: Death — 5; 5; 7; 1 Participants
Complicated Intra-abdominal Infection · Complicated Urinary Tract Infection
Primary: Percentage of Participants Experiencing ≥1 Adverse Events (AE) — 74.1 Percentage of Participants
Complicated Urinary Tract Infection · Pyelonephritis
Primary: The Percentage of Subjects Who Have Both a Per-subject Microbiological Outcome of Eradication and a Clinical Outcome of Cure at the Test of Cure (TOC) Visit in the…
Urinary Tract Infection · Acute Pyelonephritis · Hospital Acquired Pneumonia
Primary: Percentage of Participants With Clinical Cure at Test of Cure (TOC) Visit - Microbiologically Modified Intent-to-Treat (mMITT) Analysis Set — 59.3; 25.9 Percentage of…
Clostridium Difficile Infection (CDI)
Primary: Clinical Cure: Resolution of Diarrhea — 54; 44 Participants — p=0.195